Lead Product(s) : Sulanemadlin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Advancium Health
Deal Size : Undisclosed
Deal Type : Acquisition
Aileron And Advancium Sign Deal for ALRN-6924 Retinoblastoma Therapy
Details : Through the acquisition, Advancium will expand its oncology portfolio by acquiring ALRN-6924 (sulanemadlin), which is being evaluated for the treatment of retinoblastoma.
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Undisclosed
October 31, 2024
Lead Product(s) : Sulanemadlin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Advancium Health
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Sulanemadlin
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALRN-6924 is an MDM2/MDMX inhibitor that leverages Aileron’s proprietary peptide drug technology. The primary endpoint of the Phase 1b open-label trial was duration and incidence of severe neutropenia in cycle 1.
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
February 21, 2023
Lead Product(s) : Sulanemadlin
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulanemadlin,Paclitaxel
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Non-clinical data demonstrated principle that ALRN-6924 can temporarily arrest cell cycle in human scalp hair follicles and their stem cells also ALRN-6924-induced cell cycle arrest protected hair follicles from paclitaxel-induced toxicity and irreversib...
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
October 05, 2022
Lead Product(s) : Sulanemadlin,Paclitaxel
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulanemadlin
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary endpoints are duration and incidence of severe neutropenia (Grade 4) in cycle 1. Secondary endpoints include the chemoprotective effect of ALRN-6924 on chemotherapy-induced alopecia, as well as other hematologic and non-hematologic toxicities...
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
September 30, 2022
Lead Product(s) : Sulanemadlin
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulanemadlin,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALRN-6924, first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biom...
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
June 29, 2022
Lead Product(s) : Sulanemadlin,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulanemadlin,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities.
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : Sulanemadlin,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulanemadlin,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mut...
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
January 08, 2022
Lead Product(s) : Sulanemadlin,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulanemadlin,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Acorn Bioventures
Deal Size : $35.9 million
Deal Type : Public Offering
Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering
Details : Aileron is developing ALRN-6924 as a novel medicine to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy’s effects against cancer ...
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Undisclosed
November 01, 2021
Lead Product(s) : Sulanemadlin,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Acorn Bioventures
Deal Size : $35.9 million
Deal Type : Public Offering
Lead Product(s) : Sulanemadlin,Topotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A precision medicine-based chemoprotective agent, ALRN-6924 is designed to selectively activate p53 in normal cells, thereby upregulating p21, which pauses cell cycle in normal cells but not in p53-mutated cancer cells.
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
September 16, 2021
Lead Product(s) : Sulanemadlin,Topotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulanemadlin,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Initial findings from an ongoing study demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in normal bone marrow cells in healthy volunteers.
Product Name : ALRN-6924
Product Type : Peptide
Upfront Cash : Inapplicable
August 27, 2021
Lead Product(s) : Sulanemadlin,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable